» Articles » PMID: 1381718

Interleukin-7 is a Growth Factor for Sézary Lymphoma Cells

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1992 Sep 1
PMID 1381718
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Sézary syndrome is a cutaneous T cell lymphoma characterized by infiltration of the skin by CD4+ cells. These cells generally respond poorly to mitogens and T cell activators. We have studied the action of IL1 to IL4, IL6, and IL7 on the proliferation of Sézary cells from 12 patients. With the exception of IL2 and IL7, the cytokines studied had no proliferative effect on these cells. Whereas IL2 had only a low proliferative capacity (two- to threefold increase) on peripheral blood mononuclear cells, recombinant IL7 constantly induced a very significant (3-40-fold increase) proliferative response, and was used successfully to generate cell lines in three out of eight cases. Growth of Sézary cell lines was shown to be strictly dependent on IL7, and after 2-5 wk of culture presented a switch to a homogeneous phenotype CD3+4+8-7- (except for one line that remained CD7+), with a typical morphology of Sézary cells. Their tumoral origin was demonstrated by the expression of the same T cell receptor-beta gene rearrangement as the patients' T cells. Importantly, cultured normal epidermal keratinocyte supernatants could support the growth of our Sézary lines. Furthermore, the proliferative activity contained in these supernatants was completely blocked by a monoclonal anti-IL7 antibody. These results suggest that IL7 may, therefore, represent an important cytokine in the physiopathology of cutaneous T cell lymphoma.

Citing Articles

Deciphering Tumor Cell Evolution in Cutaneous T-Cell Lymphomas: Distinct Differentiation Trajectories in Mycosis Fungoides and Sézary Syndrome.

Jiang T, Cao S, Kruglov O, Virmani A, Geskin L, Falo Jr L J Invest Dermatol. 2023; 144(5):1088-1098.

PMID: 38036289 PMC: 11034798. DOI: 10.1016/j.jid.2023.10.018.


Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma.

Rindler K, Jonak C, Alkon N, Thaler F, Kurz H, Shaw L Mol Cancer. 2021; 20(1):124.

PMID: 34583709 PMC: 8477535. DOI: 10.1186/s12943-021-01419-2.


Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies.

Lodewijckx I, Cools J Pharmaceuticals (Basel). 2021; 14(5).

PMID: 34066732 PMC: 8151260. DOI: 10.3390/ph14050443.


Interleukin (IL)-7 Signaling in the Tumor Microenvironment.

Bednarz-Misa I, Bromke M, Krzystek-Korpacka M Adv Exp Med Biol. 2021; 1290:9-49.

PMID: 33559853 DOI: 10.1007/978-3-030-55617-4_2.


Xenograft and cell culture models of Sézary syndrome reveal cell of origin diversity and subclonal heterogeneity.

Poglio S, Prochazkova-Carlotti M, Cherrier F, Gros A, Laharanne E, Pham-Ledard A Leukemia. 2020; 35(6):1696-1709.

PMID: 33106625 PMC: 8179845. DOI: 10.1038/s41375-020-01068-2.


References
1.
Londei M, Verhoef A, Hawrylowicz C, Groves J, De Berardinis P, Feldmann M . Interleukin 7 is a growth factor for mature human T cells. Eur J Immunol. 1990; 20(2):425-8. DOI: 10.1002/eji.1830200228. View

2.
Welch P, Namen A, Goodwin R, Armitage R, Cooper M . Human IL-7: a novel T cell growth factor. J Immunol. 1989; 143(11):3562-7. View

3.
Alderson M, Sassenfeld H, Widmer M . Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J Exp Med. 1990; 172(2):577-87. PMC: 2188337. DOI: 10.1084/jem.172.2.577. View

4.
Touw I, Pouwels K, van Agthoven T, van Gurp R, Budel L, Hoogerbrugge H . Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood. 1990; 75(11):2097-101. View

5.
Goodwin R, Lupton S, Schmierer A, Hjerrild K, Jerzy R, Clevenger W . Human interleukin 7: molecular cloning and growth factor activity on human and murine B-lineage cells. Proc Natl Acad Sci U S A. 1989; 86(1):302-6. PMC: 286452. DOI: 10.1073/pnas.86.1.302. View